Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 7/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16704277 | 0.90 | DPP4 (0.51) | ELANEITGB3ITGA2BDPP4 | |
| SCHEMBL20859176 | 0.90 | DPP4 (0.51) | ELANEITGB3ITGA2BDPP4 | |
| SCHEMBL20853459 | 0.90 | DPP4 (0.51) | ELANEITGB3ITGA2BDPP4 | |
| SCHEMBL30814181 | 0.90 | DPP4 (0.51) | ELANEITGB3ITGA2BDPP4 | |
| SCHEMBL16704083 | 0.90 | ELANE (0.42) | ELANEITGB3ITGA2BDPP4KCNH2 | |
| SCHEMBL16704276 | 0.90 | DPP4 (0.51) | ELANEITGB3ITGA2BDPP4 | |
| Hydrochloric Acid SCHEMBL20853486 | 0.89 | DPP4 (0.51) | ELANEITGB3ITGA2BDPP4 | |
| Hydrochloric Acid SCHEMBL16704082 | 0.89 | DPP4 (0.51) | ELANEITGB3ITGA2BDPP4 | |
| Hydrochloric Acid SCHEMBL29613732 | 0.89 | DPP4 (0.51) | ELANEITGB3ITGA2BDPP4 | |
| Hydrochloric Acid SCHEMBL16704079 | 0.89 | DPP4 (0.51) | ELANEITGB3ITGA2BDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10815199-B2 | NMDA antagonist prodrugs | ASTRAZENECA AB (SE) | 2020-10-27 | — | — | US | disclosed |
| US-20190152914-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2019-05-23 | — | — | US | disclosed |
| US-20180037550-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2018-02-08 | — | — | US | disclosed |
| US-9822075-B2 | NMDA antagonist prodrugs | ASTRAZENECA AB (SE) | 2017-11-21 | — | — | US | disclosed |
| US-20160280647-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815199-B2 | NMDA antagonist prodrugs | GRIN1, GRIN2A, GRIN3A | ELANE 2956/4885ITGB3 3476/4885ITGA2B 2523/4885 |
| US-20190152914-A1 | NMDA ANTAGONIST PRODRUGS | GRIN1, GRIN2A, GRIN3A | ELANE 2956/4885ITGB3 3476/4885ITGA2B 2523/4885 |
| US-20160280647-A1 | NMDA ANTAGONIST PRODRUGS | GRIN1, GRIN2A, GRIN3A | ELANE 2956/4885ITGB3 3476/4885ITGA2B 2523/4885 |
| US-20180037550-A1 | NMDA ANTAGONIST PRODRUGS | GRIN1, GRIN2A, GRIN3A | ELANE 2956/4885ITGB3 3476/4885ITGA2B 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.